Evidence map›Paper›PMID 16501110›Full record

ArticleJournal of virology2006

Global suppression of the host antiviral response by Ebola- and Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence.

John C Kash, Elke Mühlberger, Victoria Carter, Melanie Grosch, Olivia Perwitasari, Sean C Proll, Matthew J Thomas, Friedemann Weber, Hans-Dieter Klenk, Michael G Katze

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 121 papers.

0numbers the graph read from it
0cells of the map it votes in
121citing papers in PubMed
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

121 citing papers in PubMed, 175 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article

61 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

John C KashDepartment of Microbiology, School of Medicine, University of Washington, Box 358070, Seattle, Washington 98195-8070, USA. jkash@u.washington.edu
Elke Mühlberger
Victoria Carter
Melanie Grosch
Olivia Perwitasari
Sean C Proll
Matthew J Thomas
Friedemann Weber
Hans-Dieter Klenk
Michael G Katze
Philipps University of Marburg · DEUniversity of Washington · USUniversity of Freiburg · DE

Funding

Viral and Host cDNA Libraries from 1918 Influenza CasesP01AI058113 · NIAID · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI GARCIA-SASTRE, ADOLFO · 2004 to 2010
$20.3M
PROTEOMICS COREP30DA015625 · NIDA · UNIVERSITY OF WASHINGTON · PI KATZE, MICHAEL G · 2002 to 2012
$18.9M
Proteomic Analysis of the Innate Antiviral ResponseR21AI056214 · NIAID · UNIVERSITY OF WASHINGTON · PI KATZE, MICHAEL G · 2003 to 2004
$516k
NIAID NIH HHS AI056214-02NIAID NIH HHS AI058113-01NIAID NIH HHS P01 AI058113NIAID NIH HHS R21 AI056214NIDA NIH HHS DA15625-03NIDA NIH HHS P30 DA015625
6 · The paper itself

Abstract

We studied the effect of filovirus infection on host cell gene expression by characterizing the regulation of gene expression responses in human liver cells infected with Zaire Ebolavirus (ZEBOV), Reston Ebolavirus (REBOV), and Marburgvirus (MARV), using transcriptional profiling and bioinformatics. Expression microarray analysis demonstrated that filovirus infection resulted in the up-regulation of immune-related genes and the down-regulation of many coagulation and acute-phase proteins. These studies further revealed that a common feature of filovirus virulence is suppression of key cellular antiviral responses, including TLR-, interferon (IFN) regulatory factor 3-, and PKR-related pathways. We further showed that ZEBOV and MARV were more potent antagonists of the IFN response and inhibited the expression of most of the IFN-stimulated genes (ISGs) observed in mock-infected IFN-alpha-2b treated cells, compared to REBOV infection, which activated more than 20% of these ISGs. Finally, we examined IFN-related gene expression in filovirus-infected cells treated with IFN-alpha-2b. These experiments revealed that a majority of genes induced in mock-infected cells treated with type I IFN were antagonized in treated ZEBOV- and MARV-infected cells, while in contrast, REBOV infection resulted in a significant increase in ISG expression. Analysis of STAT1 and -2 phosphorylation following IFN treatment showed a significant reduction of STAT phosphorylation for MARV but not for ZEBOV and REBOV, indicating that different mechanisms might be involved in antagonizing IFN signaling pathways by the different filovirus species. Taken together, these studies showed a correlation between antagonism of type I IFN responses and filovirus virulence.

Indexed as

Gene Expression RegulationAnimalsAntiviral AgentsCell Line, TumorChlorocebus aethiopsEbolavirusHumansInterferon Type IMarburgvirusOligonucleotide Array Sequence AnalysisProteinsVero CellsVirulenceAntiviral AgentsInterferon Type IProteins

Identifiers

PMID16501110
PMCPMC1395418
OpenAlexW2160999690

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.